New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
16:24 EDTLPCNLipocine announces first patient dosed in Phase 2a study of LPCN 1111
Lipocine announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The primary objectives of the study will be to determine safety, tolerability, single and steady state pharmacokinetics of testosterone following oral administration of LPCN 1111.
News For LPCN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
13:33 EDTLPCNLipocine reports 'acceptable' LPCN 1021 results
In a regulatory filing earlier, Lipocine provided data on its phase 3 SOAR study of LPCN 1021, an oral testosterone product. The company first presented the data at the American Urological Association meeting on May 18. According to the presentation, LPCN 1021 produced "acceptable" results which were "generally consistent" with U.S. FDA target guidelines. The company notes that LPCN 1021 "may" improve patient compliance.
09:08 EDTLPCNLipocine appoints Dr. Jyrki Mattila as Chief Business Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use